

RECORDATI: 2020 CORPORATE EVENTS' CALENDAR

Milan, 12th November 2019 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2020:

14th February	Board of Directors' meeting to approve the 2019 preliminary consolidated results.
18th March	Board of Directors' meeting to approve the 2019 consolidated financial statements and the draft of Recordati S.p.A.'s 2019 financial statements as well as the 2019 consolidated non-financial statement.
30th April	Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2019 financial statements.
7th May	Board of Directors' meeting to approve the 2020 first quarter results ¹ .
30th July	Board of Directors' meeting to approve the 2020 half-yearly report.
29th October	Board of Directors' meeting to approve the 2020 first nine months' results ² .

Recordati S.p.A. announces that the payment of the balance of the 2019 financial year dividend is planned for 20th May 2020, on each outstanding share at 18th May 2020 (ex-dividend date) and record date 19th May 2020, while payment of the interim dividend for the 2020 financial year is planned for 25th November 2020, on each outstanding share at 23rd November 2020 (ex-dividend date) and record date 24th November 2020.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati

¹ Please be reminded that, as a result of the fact that Italian Legislative Decree n. 25/2016 enacting Directive 2013/50/EU eliminated the mandatory requirement to disclose the interim financial report, Recordati S.p.A. has decided, pursuant to art.82-ter of Issuers Regulation, to continue disclosing the quarterly reports, on a voluntary basis and until any different decision is taken in this respect, with comparable form and content to those of the previous financial years.

² Please see note n.1 above.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale

VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150
CODICE FISCALE/P. IVA 00748210150
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l



is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2018 was € 1,352.2 million, operating income was € 442.2 million and net income was € 312.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.